ColdstartMHDTI is proposed, a two-stage framework for heterogeneous-graph-based DTI prediction that integrates sequence-derived structural representations with local and global relational information and supports candidate prioritization for downstream screening and evidence-guided hypothesis generation.
Abstract
Motivation Accurate drug–target interaction (DTI) prediction remains difficult for underexplored drugs and targets, especially when available interaction evidence is sparse. Existing approaches often focus either on pairwise molecular representations or on heterogeneous biomedical graph topology, making it difficult to effectively integrate structure-derived representations with multi-relational contextual evidence. Result We propose ColdstartMHDTI, a two-stage framework for heterogeneous-graph-based DTI prediction that integrates sequence-derived structural representations with local and global relational information. Specifically, drug SMILES and target sequences are encoded by pretrained transformer models, while one-hop heterogeneous relations are captured through self-supervised DistMult embeddings. These representations are then fused through a meta-path-guided module that models ordered meta-path instances and aggregates them with cross-attention for interaction scoring. Across two benchmark datasets, ColdstartMHDTI shows consistent improvements under warm-start and entity-disjoint settings, with particularly strong performance for underexplored drugs and targets. It also remains robust under more imbalanced evaluation protocols with 1:5 and 1:10 positive-to-negative ratios. In addition to standard classification performance, ColdstartMHDTI supports candidate prioritization for downstream screening and evidence-guided hypothesis generation. Case studies on ESR1, EGFR, and Parkinson’s disease further demonstrate its practical utility, with the Parkinson’s disease analysis additionally highlighting strong per-drug target ranking performance.
A multi-modal deep learning framework to predict drug-target affinity by integrating sequence semantics with graph structural information and design a new symmetric dual cross-attention fusion mechanism for drugs and targets.
Wei Lan, Tian Huang, Guohang He et al.· IEEE journal of biomedical a...· 0 citations
This work proposes GraphTransDTI, a synergistic hybrid framework that integrates a Graph Transformer to represent drug graph structures, a CNN-BiLSTM network to encode protein sequence context, and a Cross-Attention mechanism to model cross-domain interactions.
Vang V. Le, Mai Thi Anh Nhu, Pham Truong Viet Thong· PLoS ONE· 0 citations
Predicting drug–target interactions is critical for drug discovery, yet many deep learning methods overlook atom–residue–level relationships, so PHGDTI is proposed, a multimodal framework that integrates sequence and structural cues for binding prediction.
Hua Qian, Deng Pan, Liangpeng Nie et al.· Journal of Computational Bio...· 0 citations
EBD-DTI is presented, a framework that enables zero-shot inference in graph-based DTI models without requiring any known interactions for unseen entities, with episodic cold-start training improving AUC by up to 12%.
Jiongxin Liu, Jiameng Le, Chuanru Wei et al.· bioRxiv· 0 citations
SGTL-DDA is proposed, a novel graph transformer framework designed to incorporate structural information and domain-specific knowledge from heterogeneous biological information networks (HBINs) that successfully identifies both known therapeutics and novel repositioning candidates, supported by molecular docking result...
Bowei Zhao, Hui Zhao, Yu-An Huang et al.· IEEE transactions on computa...· 0 citations
Experiments show that GraESM-FuseDTA achieves competitive overall performance and consistent advantages in ranking-oriented and variance-explanation metrics across warm start, drug cold start, target cold start, and strict pair cold start settings.